Vertex reported first‑quarter 2026 revenue of $2.99 billion, falling short of consensus estimates of $3.03‑$3.09 billion and missing by roughly $0.04‑$0.10 billion. The 8% year‑over‑year increase reflects growth in the cystic fibrosis franchise, but the shortfall is driven by lower‑than‑expected sales of newer launches CASGEVY and JOURNAVX, each missing analyst estimates by double‑digit percentages.
Adjusted earnings per share rose to $4.47, beating consensus estimates of $4.23‑$4.33 by $0.14‑$0.24. The beat is largely attributable to disciplined cost management and the high‑margin mix of the core CF portfolio, particularly the rapid adoption of ALYFTREK, which generated $424.4 million in the quarter, offsetting a 7% decline in TRIKAFTA/KAFTRIO revenue of $2.35 billion.
Vertex reiterated its full‑year 2026 revenue guidance of $12.95 billion to $13.10 billion, unchanged from prior guidance, indicating management confidence in continued demand across its diversified portfolio. Non‑GAAP operating income reached $1.31 billion, with margins expanding to 44% from 43% year‑over‑year, driven by the higher‑margin CF products and improved operational leverage.
Management highlighted the strong performance of the CF franchise and the contribution of non‑CF products, noting that CASGEVY and JOURNAVX together accounted for more than 25% of the quarter’s year‑over‑year growth. The company also announced the discontinuation of its VX‑522 mRNA CF program due to tolerability issues, reallocating resources to other pipeline candidates.
Market reaction was muted, with investors focusing on the revenue miss despite the EPS beat. The shortfall in CASGEVY and JOURNAVX sales, combined with the decline in TRIKAFTA/KAFTRIO, tempered enthusiasm for the company’s growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.